These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 16925109

  • 21. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
    Molina M, García Hernández MA, Navarro MJ, Pérez Silva F, Cacho M, De Gracia MC.
    Nefrologia; 2004; 24(1):54-9. PubMed ID: 15083958
    [Abstract] [Full Text] [Related]

  • 22. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
    Hoggard J, Crouch T, McMurray S, Levine M, Prathikanti R, Scarlata D, Audhya P.
    Curr Med Res Opin; 2006 Oct; 22(10):2023-30. PubMed ID: 17022861
    [Abstract] [Full Text] [Related]

  • 23. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
    Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, Picarello N, McDermott-Vitak A, Maroni BJ.
    Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568
    [Abstract] [Full Text] [Related]

  • 24. Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT).
    Martelli O, Garassino M, Sacchetta S, Caristo R, Zivi A, Cerbone L, Mancuso A.
    Anticancer Res; 2008 Jul; 28(3B):1767-71. PubMed ID: 18630457
    [Abstract] [Full Text] [Related]

  • 25. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
    Nurko S, Spirko R, Law A, Dennis VW.
    Clin Ther; 2007 Sep; 29(9):2010-21. PubMed ID: 18035200
    [Abstract] [Full Text] [Related]

  • 26. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice.
    Patton J, Reeves T, Wallace J.
    Oncologist; 2004 Sep; 9(4):451-8. PubMed ID: 15266098
    [Abstract] [Full Text] [Related]

  • 27. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies.
    Hesketh PJ, Arena F, Patel D, Austin M, D'Avirro P, Rossi G, Colowick A, Schwartzberg L, Bertoli LF, Cole JT, Demetri G, Dessypris E, Dobbs T, Eisenberg P, Fleischman R, Hall J, Hoffman PC, Laber DA, Leonard J, Lester EP, McCachren S, McMeekin S, Meza L, Miller DS, Nand S, Oliff I, Paroly W, Pawl L, Perez A, Raftopoulos H, Rigas J, Rowland K, Scullin DC, Tezcan H, Waples J, Ward J, Yee LK.
    Cancer; 2004 Feb 15; 100(4):859-68. PubMed ID: 14770445
    [Abstract] [Full Text] [Related]

  • 28. Darbepoetin alfa: potential role in managing anemia in cancer patients.
    Pirker R, Smith R.
    Expert Rev Anticancer Ther; 2002 Aug 15; 2(4):377-84. PubMed ID: 12647980
    [Abstract] [Full Text] [Related]

  • 29. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
    Song X, Long SR, Marder WD, Sullivan SD, Kallich J.
    Ann Pharmacother; 2009 Jul 15; 43(7):1203-10. PubMed ID: 19584392
    [Abstract] [Full Text] [Related]

  • 30. Darbepoetin alfa: impact on treatment for chemotherapy-induced anemia and considerations in special populations.
    Vansteenkiste J, Poulsen E, Rossi G, Glaspy J.
    Oncology (Williston Park); 2002 Oct 15; 16(10 Suppl 11):45-55. PubMed ID: 12435173
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Clinical trial simulation of a 200-microg fixed dose of darbepoetin alfa in chemotherapy-induced anemia.
    Jumbe N, Yao B, Rovetti R, Rossi G, Heatherington AC.
    Oncology (Williston Park); 2002 Oct 15; 16(10 Suppl 11):37-44. PubMed ID: 12435172
    [Abstract] [Full Text] [Related]

  • 35. Darbepoetin alfa: new indication/new dosage. No proven advantage in chemotherapy-induced anaemia.
    Prescrire Int; 2005 Oct 15; 14(79):174-6. PubMed ID: 16285072
    [Abstract] [Full Text] [Related]

  • 36. An overview of the pharmacokinetic disposition of darbepoetin alfa.
    Zamboni WC, Stewart CE.
    Pharmacotherapy; 2002 Sep 15; 22(9 Pt 2):133S-140S. PubMed ID: 12222583
    [Abstract] [Full Text] [Related]

  • 37. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
    Reed SD, Radeva JI, Daniel DB, Mody SH, Forlenza JB, McKenzie RS, Schulman KA.
    Pharmacoeconomics; 2006 Sep 15; 24(5):479-94. PubMed ID: 16706573
    [Abstract] [Full Text] [Related]

  • 38. The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia.
    Ben-Hamadi R, Duh MS, Aggarwal J, Henckler A, McKenzie RS, Tak Piech C.
    Curr Med Res Opin; 2005 Oct 15; 21(10):1677-82. PubMed ID: 16238908
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Extended-dosage-interval regimens of erythropoietic agents in chemotherapy-induced anemia.
    Muller RJ, Baribeault D.
    Am J Health Syst Pharm; 2007 Dec 15; 64(24):2547-56. PubMed ID: 18056942
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.